** Shares of drug developer Kineta rise 13.5% to 64 cents
** Co says it has resumed enrollment, effective immediately, for its ongoing early-stage trial testing its experimental cancer treatment- KVA12123
** Co previously said enrollment was suspended "due to certain investors indicating that they would not fulfill their funding obligation due in April 2024"
** Co says 30 patients have been enrolled in the trial to date, including a monotherapy arm with just KVA12123 and a combination arm testing KVA12123 together with Merck's Keytruda
** Anticipates the trial to be fully enrolled by the end of 2024- KA
** Co says initial results of KVA12123 showed a favorable clinical safety and tolerability profile
** Including session moves, stock down 82.1% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Comments